Amitriptyline

Speaker 1...and this brings us to amitriptyline, a common treatment for various pain conditions. It works by boosting serotonin and norepinephrine and blocking sodium channels. The idea is that by alleviating chronic pain, we might improve quality of life, and perhaps even slow down biological aging, which untreated pain can accelerate.

Speaker 2Exactly. Chronic pain, like painful diabetic neuropathy, has been linked to accelerated epigenetic aging and telomere shortening, according to a study in GeroScience in 2025. So, addressing pain is crucial. But with amitriptyline, there's a nuance.

Speaker 1Right. While effective for pain in many, amitriptyline belongs to a class of drugs with anticholinergic properties. Cumulative use of these anticholinergics has been associated with an increased risk for dementia. A 2015 study in JAMA Internal Medicine found a 54% higher risk, with tricyclic antidepressants being the most commonly used class.

Speaker 2That's a significant finding. It highlights the complex interplay between managing pain and potential long-term risks, especially for an aging population. We need to weigh the immediate benefits of pain relief against these documented long-term harms like cognitive decline.

Speaker 1So, it's not simply a matter of treating pain to slow aging. The *way* we treat it matters. The evidence doesn't fully establish whether amitriptyline, despite relieving pain, ultimately improves or harms overall biological aging and all-cause mortality in the long run, beyond this dementia link.

Speaker 2Precisely. For some, the pain relief is life-changing, and under supervision, it's a legitimate option. But the long-term impact on all-cause mortality and overall biological aging from amitriptyline use itself remains less clear and needs more research.